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Highlights:  
1) Multiple clinical trials are currently testing shortened drug regimens for MDR/XDR-TB, 
including with all oral regimens in study arms 
2) Newly developed drugs such as Bdq and Dlm provide new treatment options for 
MDR/XDR-TB. 
3) If trials are successful, treatment for MDR/XDR-TB could be reduced to 6-9 months as 
standard. 
4) By 2022 best practice for managing MDR/XDR-TB will be informed by substantial 
clinical trial data 
5) Re-purposing of existing drugs has proved useful in treatment of MDR/XDR-TB 
 
Tuberculosis (TB) is the top infectious disease cause of death worldwide. According to the latest World 
Health Organization Global Tuberculosis Report (WHO Report, 2018a), in 2017 TB was responsible for 
an estimated 1.3 million deaths among HIV-negative people and 300,000 deaths among HIV-positive 
people.  There were 558,000 new cases of Rifampicin (Rif) resistant TB (RR-TB), 82% of which were 
resistant to at least Isoniazid as well (MDR-TB), and 8.5% with additional resistance to both a 
fluoroquinolone and a second-line injectable  - extensively resistant (XDR-TB) (WHO Report, 2018a). 
These figures are alarming and emphasize that the chance of someone being cured and becoming 
disease free long-term decreases with increasing drug resistance, from over 85% for drug-susceptible 













The relentless spread of MDR-TB and the high mortality rates are fuelled by the limited ability to test 
for resistance in resource-constrained settings, intermittent access to drugs, lack of useful alternative 
drugs, significant drug adverse effects, and poor adherence to medication continues. This in part reflects 
the inadequacy of the non-first line drug therapies for TB. To be effective, they need to be given for 
considerably longer; and therefore, the WHO guidelines for programmatic management of drug-
resistant tuberculosis, updated in 2011 recommended that treatment for MDR-TB should remain at a 
staggering 20 months, including an injectable drug for at least 8 months and the use of a fluoroquinolone 
(WHO 2011). Up to that point, detection of resistant strains of Mycobacterium tuberculosis (M.tb) 
involved sophisticated culture-based susceptibility testing - often taking weeks to get results. In 
addition, these tests were generally not available in high TB incidence countries where there was the 
greatest need.  
 
The landscape for detection of resistance was changed by introduction of rapid molecular tests such as 
lineprobe assays and the GeneXpert MTB-RIF Assay (Boehme et al., 2010) which simultaneously 
detects M.tb DNA and Rif-resistance. The GeneXpert system, for the first time, gave an option for the 
drug regimen to be better selected, by detection of Rif resistance in real time. Endorsed by the WHO 
(WHO 2010), it has successfully provided simple, effective detection MDR-TB, since Rif resistance is 
most commonly secondary to isoniazid (INH) resistance. Despite this, drug sensitivity testing for non-
standard Rif mutations and other drugs remains a lengthy process requiring culture-based methods or 
increasingly the application of whole genome sequencing. 
 
Following a diagnosis of MDR-TB it is estimated that only about two-thirds of treated cases have 
positive outcomes (Falzon et al., 2013). This is even worse for XDR-TB at 40% (Falzon et al., 2013) 
and reflects the lack of available options for healthcare workers to treat MDR/XDR-TB, poor tolerance 













In contrast to DS-TB, where treatment is informed by carefully conducted trials to determine 
combination treatment efficacy, until 2016 therapy for MDR/XDR-TB was largely empirical and based 
on expert opinion. The WHO treatment guidelines for drug-resistant tuberculosis, released in 2016 
reflected the first big shift in treatment recommendations for MDR-TB, informed by several 
observational studies in multiple countries (WHO 2016). Cohort studies in Bangladesh recruited 206 
patients with MDR-TB and after consecutively testing 6 different drug combinations, found 9 months’ 
treatment with gatifloxicin (Gfx), clofazimine (Cfz), ethambutol (Emb) and pyrazinamide (Pza), 
supplemented by prothionamide (Pto), kanamycin (Km) (injectable) and high-dose isoniazid (INH) 
resulted in a relapse-free cure in 87.9% (CI 82.7-91.6) of individuals (Van Deun et al., 2010). Several 
meta-analyses including one of 9,153 patients from 32 observational studies identified treatments 
associated with improved response, such as the use of later-generation fluoroquinolones, and use of 4 
or more likely-effective drugs during the intensive treatment phase, though concluded in highlighting 
the urgent need for randomised trials (Ahuja et al., 2012). The positive results seen in cohort studies led 
to a change in the WHO guidelines to recommend that RR-TB and MDR-TB treatment time could be 
reduced from 20 months to 9-12 months provided that patients have had no previous treatment with 
second-line TB drugs and where resistance to fluoroquinolones and second-line injectable drugs was 
excluded or not expected (WHO 2016). 
 
The STREAM trial 
The change in WHO guidelines in 2016 was informed by the non-randomised cohort studies, and again 
highlighted the lack of controlled clinical trial data. Although in 2012, the STREAM trial had started 
recruitment as the first-ever phase III, randomised controlled clinical trial testing a shorter MDR-TB 
regimen, even the early data were only available in 2017. It was to be the first open-label, multi-centre 
study setup to test the safety and effectiveness of a ‘shorter regimen’ (40-48 weeks) (based on the 
Bangladesh cohort study findings) and to compare it to the 18-24 months previous standard.  The drug 
regimen was the same as the Bangladesh study except that Gfx was replaced with Moxifloxacin (Mfx) 













The preliminary results of STREAM stage 1 were released in late 2017 at the 48th Union World 
Conference on Lung Health and followed by WHO key changes to treatment of multidrug- and 
rifampicin-resistant tuberculosis in August 2018 (WHO 2018b). Although not fully supporting non-
inferiority, when compared to the standard treatment for MDR-TB, the STREAM stage 1 trial results 
reported that under trial conditions a nine-month regimen could be effective in 78.1% of those with 
MDR-TB compared to 80.6% of those on the standard 20 month’s treatment. It should be noted that, 
under clinical trial conditions, the 20-month treatment arm outperformed the expected 54% success 
generally recorded in non-trial conditions.  There are several potential further benefits to be considered 
for shorter regimens such as improved compliance, less side-effects due to taking the drugs for a shorter 
period, and potential cost reductions (demonstrated in the preliminary analysis for the Ethiopia site for 
both patients and the health system). There was no difference found in the number of patients with 
adverse events in the study versus the control.  Based on the findings of the preliminary analysis, the 
WHO recommendations for using shorter course therapy under specific circumstances remain in place 
to date (WHO 2018b).  
 
Two further studies evaluated the Bangladesh regimen for 12 months (with a minimum intensive phase 
of 4 months). Both found favourable outcomes (Kuaban et al., 2015) (Piubello et al., 2014). 
 
STREAM trial stage 2  
The 9-month regimen did not contain any novel drugs but was composed entirely of historically-tested 
drugs. Encouragingly it revealed that even without new anti-bacterial agents improved outcomes were 
possible for many patients presenting with MDR-TB. 
 
STREAM stage 2 extends the results of STREAM stage 1, by introducing trial arms for MDR-TB that 
replace the injectable drug with bedaquiline (Bdq) (Sirturo, TMC207). Bdq, first discovered in 2004, 
was fast-tracked by the FDA and approved for use, in combination with other drugs, for treatment of 
MDR and XDR-TB in 2012. The drug is currently being tested in STREAM stage 2 and other clinical 












electrocardiograms (ECG); and a reported increased risk of death in the Bdq arm of a phase 2b clinical 
trial (Diacon et al., 2014). This led to initial caution by the WHO in recommending its use. This was 
despite the investigators within the study not attributing the increased number of deaths to the use of 
Bdq. In support of this, a large retrospective cohort study of individuals with MDR/XDR-TB in South 
Africa, found that adding Bdq to a treatment regimen was associated with a reduction in all-cause 
patient mortality (Schnippel et al., 2018). Having a pill-only regimen would be a considerable additional 
advantage for patients, when taken together with the reduced treatment time. Additionally, the study 
has a 6-month treatment arm. It cannot be overstated the significant advance if some patients with 
MDR-TB could be treated for the same duration as currently recommended for fully DS-TB.  The study 
started enrolling in March 2018 and the results are likely to be available in 2021.  
 
Phase 3 Trials with new and re-purposed drugs 
Delamanid (Dlm) was made available by Otsuka and used in the Otsuka trial 213 to determine the 
efficacy of Dlm in treating MDR-TB in combination with other drugs for 6 months. It was a multi-
centre study where 341 patients received Dlm in addition to an optimised standard treatment, whilst 
170 received placebo instead of Dlm. Although use of Dlm led to quicker culture conversion, favourable 
results at 24 months were similar between the placebo and Dlm arms. These results were first presented 
at the 48th Union World Conference in 2017 and recently fully reported (von Groote-Bidlingmaier et 
al., 2019). 
 
Pretomanid (Pa), a drug with a novel mechanism, has shown good efficacy against in vitro tested TB 
isolates resistant to other drugs (Lenaerts et al., 2005); whilst animal studies suggested it is active 
against both replicating and non-replicating M. tuberculosis (Tyagi et al., 2005). Notably Pa appears to 
have less side-effects than Bdq (Ginsberg et al., 2015) (Dawson et al., 2015) making it an excellent 
candidate to test in new MDR and XDR-TB regimens. 
 
Linezolid (Lzd), active against gram positive bacterial organisms and licenced to treat MRSA, has been 












treatment options for patients. Studies in 2012 suggested that Lzd was effective in patients with no other 
treatment options left: 79% culture-converted after 4 months using the drug (Lee et al., 2012). This was 
also supported by PET/CT imaging in both macaques and humans using Lzd monotherapy for XDR-
TB (Coleman et al., 2014). However, there were issues regarding patient tolerance and adverse events, 
such as optic neuropathy. Recent meta-analyses suggest that Lzd is positively associated with MDR-
TB treatment success (Collaborative Group for the Meta-Analysis of Individual Patient Data in et al., 
2018) (Sotgiu et al., 2012). 
 
Several clinical trials are testing the efficacy and safety of combinations of new and re-purposed drugs 
and their results will be known in 2-3 years. TB Alliance in partnership with PanACEA is evaluating a 
Bdq, Pa, Mfx and Pza regimen (SimpliciTB) and attempting to show efficacy treating for 6 months 
using an all oral treatment course for MDR-TB. The results won’t be available until 2022. 
 
The NexT-5001 trial, run by the University of Cape Town, is testing 6-9 months of Bdq, Lzd, 
Levofloxicin (Lfx), Pza and either high-dose INH or ethionamide (Eto) or terizidone (Trd) daily (an all 
oral regimen) versus a conventional empiric injection-based regimen consisting of an intensive phase 
of  6-8 months kanamycin (Km), Mfx, Pza, Eto, Ter daily and an 18 month continuation phase of Mfx, 
Pza, Ter for both MDR and XDR-TB cases. The results of this study should be available in early 2019. 
 
The endTB study (a partnership between Partners in Health, Médecins Sans Frontières, Interactive 
Research & Development and financial partner UNITAID) is testing whether using the new drugs Dlm 
and Bdq can benefit patients by providing a shorter, less toxic and injection-free treatment course for 
MDR-TB. The study results are projected to be available in 2022. The regimens consist of 5 
combinations of drugs including Bdq, Lzd, Mfx, Pza, Cfz, Dlm, Lfx all for 9 months.  
 
Notably the WHO report released in 2018 gave a revised grouping of TB medicines recommended for 
use in longer MDR-TB regimens with agents selected grouped into 3 categories and chosen in 












highlights the expected benefit of adding Bdq and Lzd to the MDR-TB regimen despite some of the 
potential toxicities of these drugs. Those in group B are added next: Cfz, Trd/cycloserine and then group 
C, which are selected to complete the regimen and when agents from A and B cannot be used: Emb, 
Dlm, Pza, imipenem-cilastatin, meropenem, amikacin (streptomycin), Eto/Pto, p-amino salicyclic acid. 
There are also recommendations for regimen design to take into account whether there are drug-
susceptibility testing results available, the preference for an oral drug over an injectable and the drug 
resistance levels in the local population (WHO 2018b). A summary of the drugs described in this article 
are given in Table I. 
 
XDR-TB 
What about XDR-TB?  The STREAM trials exclude patients with XDR-TB. However, NiX-TB using 
an open-label design, and commenced in 2015, is the first pill-only trial for XDR-TB. It is testing a 
combination of novel and re-purposed drugs; and moves away from using current, conventional anti-
TB drugs completely with its combination of Bdq, Lzd and Pa (BPaL) (TB Alliance).  Also it aims to 
reduce treatment time to 6-9 months. If successful the study could transform the treatment of XDR-TB 
by providing an injection-free regimen. The preliminary results reported at CROI 2017 were promising, 
with 86.7% of 30 patients relapse-free during 6 months follow-up, and the toxicity due to Lzd being 
manageable (Conradie et al., Croi 2017). Since it was open-label, the NiX-TB trial could be adapted, 
based on early study outcomes. This has informed another TB Alliance Trial - ZeNix, which began 
recruiting in 2018. It is also testing BPaL but with different arms, including a reduced Lzd concentration 
to better determine the balance between efficacy and toxicity. It is recruiting patients with both MDR 
and XDR-TB. 
The Médecins Sans Frontières (MSF) sponsored study TB-PRACTECAL study is testing 3 different 
treatment arms including combinations of Bdq, Pa, Mfx, Lzd, Cfz for 6 months, with a comparator 
treatment being the locally accepted standard of care, consistent with the WHO recommendation. The 













An additional study, running at the same sites as the endTB study, is the endTB-Q study for individuals 
with fluoroquinolone resistance and includes a 6-month arm and a 9-month arm with no quinolone 
included in the regimen.  All of the clinical trials discussed here are summarised in Table 2. 
 
Summary 
Based on both already published results and ongoing studies it is clear the landscape is changing in a 
positive way for treatment of both MDR and XDR-TB. The new clinical trials will provide a rigorous 
assessment of the drugs that are currently available in Phase III or beyond, and generate a large data set 
from multiple countries that can better inform the management of drug-resistant TB. Once trials have 
informed the optimal regimens some risks and issues will still need to be resolved. These will include 
how to financially support usage of drugs, such as Lzd and Bdq, in resource-constrained settings with 
their substantially higher costs, and potential issues of patient-adherence outside of the clinical trial 
setting, particularly with all oral regimens.   There is also the compromise between restricting the use 
of new drugs to minimise the development of resistance, and making them available at scale to enhance 
available regimens. With increasing demand for these drugs, the potential for generic drug production 
to reduce costs plus the encouragement of ‘goodwill’ by partnerships with pharmaceutical companies, 
it is hoped that these issues can be overcome.  
 
In parallel with bactericidal drugs there is also the potential for adjunctive therapies. Host-directed 
therapies could potentially be used in synergy with optimised drug regimens to boost or protect the host 
tissues or cells. Therapies could include corticosteroids, TNF-α inhibitors, phosphodiesterase inhibitors 
and matrix-metalloproteinases (Ordonez et al., 2014), as well as infusion of autologous mesenchymal 
stromal cells (Skrahin et al., 2014).  With recent advances in rapid molecular drug susceptibility testing 
(Xie et al., 2017) and judicious prescribing stewardship of the newly available drugs, including an all 
oral treatment regimen (WHO 2018b) we anticipate a substantial impact on the treatment of MDR and 
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Table 1: Summary of the drugs in this article including existing, re-purposed, re-used and new drugs  





Amikacin Ami Aminoglycoside. Inhibits protein synthesis  Re-purposed Gram-negative infections resistant to gentamicin 
Bedaquiline Bdq Blocks proton pump for ATP synthase of mycobacteria New N/A 
Clofazimine Cfz Inhibits bacterial proliferation + increases bacterial 
phospholipase A2 which are toxic 
Re-purposed Leprosy 
Cycloserine Cs Inhibits cell wall synthesis Existing N/A 
Delamanid Dlm Blocks manufacture of mycolic acids, destabilising the bacterial 
cell wall 
New N/A 
Ethambutol Emb Obstructs formation of the bacterial cell wall Existing N/A 
Ethionamide Eto Inhibits InhA, thought to inhibit synthesis of mycolic acid   Existing N/A 
Gatifloxicin Gfx Inhibits bacterial DNA gyrase and topisomerase IV Re-purposed Gram-negative and positive organisms 
 
Respiratory tract and eye infections 
Imipenem-cilistatin I/C Inhibition of cell wall synthesis Re-purposed Aerobic & anaerobic Gram-positive and Gram-negative 
infections 
Isoniazid Inh Inhibits mycolic acid synthesis Existing N/A 
Kanamycin* Km Aminoglycoside. Inhibits protein synthesis  Existing N/A 
Levofloxicin Lfx Inhibitor of DNA gyrase, a type II topoisomerase  Re-purposed Wide range of bacterial infections 
Linezolid Lzd Suppresses bacterial protein production Re-purposed Gram positive infections 
Meropenem Mem Inhibition of cell wall synthesis Re-purposed Aerobic & anaerobic Gram-positive and Gram-negative 
infections 
Moxifloxicin Mfx Inhibitor of DNA gyrase, a type II topoisomerase  Re-purposed Wide range of infections, including CAP 
p-amino salicylic 
acid 
PAS Precise mechanism not fully characterised Re-used N/A 
Pretomanid Pa Cell wall inhibition and respiratory toxicity New N/A 
Prothionamide Pto Inhibits InhA and mycolic acid synthesis Re-used 
(interest waned due to 
poor tolerability) 
N/A 
Pyrazinamide Pza Cause accumulation of pyrazinoic acid inside the bacillus Existing N/A 
Streptomycin  Aminoglycoside. Inhibits protein synthesis Existing N/A 
Terizidone Trd Inhibits cell wall synthesis (a structural analogue of cycloserine) Existing  N/A 
 














Table 2 – Summary of trials described in this article 
Trial, Sponsor 
& recruitment countries 



















Recruited: 511 participants 
341 received Dlm + OBR 
OR 
170 received placebo + 
OBR 
MDR only 18-24 mths 2011 2017 18-69 years 
 
No clinically relevant difference between the 2 
study arms 
STREAM stage 1 
(ISRCTN78372190) 
Sponsor: IUATLD, Inc 
Countries (4):  
Vietnam/Mongolia/Ethiopia/ 
South Africa 
Recruited: 424 participants 
WHO standard (18-24 
mths) OR 
Mfx, Cfz, Emb, Pza, Pto, 
Km & high dose Inh (40-48 
wks) 
 




Includes adults ≥18 yrs 
 
78.1% efficacy in 9 month arm vs 80.6% in 
control arm 
STREAM stage 2 
(NCT02409290) 
Sponsor: IUATLD, Inc 
Countries (8):  
Mongolia/Ethiopia/South Africa 
Moldova/Georgia/India/ Uganda 
Target: 1155 participants 
A: WHO standard 
B: Cfz, E, Mfx, Pza (40 
wks)+ INH, Km, Pto (1st 16 
wks) 
C: Bdq, Cfz, E, Lfx, Pza (40 
wks) + Inh & Pto (1st 16 
wks) 
D: Bdq. Cfz, Lfx, Pza (28 




7 mths 2016 2021 Includes children ≥15 yrs 
 







Target: 750 participants 
1: Bdq, Lzd, Mfz, Pza (9 
mths) 
2: Bdq, Cfz, Lzd, Lfx, Pza 
(9 mths) 
3. Bdq, Dlm, Lzd, Lfx, Pza 
(9 mths) 
4. Dlm, Cfz, Lzd, Lfx, Pza 
(9ths) 
5. Dlm, Cfz, Mfz, Pza 
(9ths) 
MDR only 9 mths 2016 2022 Includes children ≥15 yrs 
 





















Target: 500 participants 
1: Bdq, Dlm, Cfz, Lzd (6 
mths) 
2: Bdq, Dlm, Cfz, Lzd (9 
mths) 
3: WHO standard  
MDR/XDR 6 mths 2019 2022 Includes children ≥15 yrs 
 








Recruited: 109 participants 
Bdq, Pa, Lzd (6 mths) + 
option of 9 mths for those 










6 mths 2015 Preliminary results: 
2017 
Full results: 
expected Feb 2019 
Includes children ≥14 yrs  
 
Study has an adaptive design to incorporate 








Target: 180 participants 
1. 1200mg Lzd, Pa, Bdq (26 
wks) 
2. 1200mg Lzd (9 wks) + 
Pa & Bdq for 26 wks 
3. 600mg Lzd, Pa & Bdq 
for 26 wks  
4. 600mg Lzd (9 wks) +Pa 








26 wks 2018 2022 Includes children ≥14 yrs  
 
If week 16 sample remains culture positive 






Target: 630 participants 
1. Bdq, Pa, Mfz, Lzd (6 
mths) 
2. Bdq, Pa, Lzd, Cfz (6 
mths) 
3. Bdq, Pa, Lzd (6 mths) 
4. WHO standard  
MDR/XDR 6 mths 2017 2021 Includes adults ≥18 yrs 





Countries (1):  
South Africa 
Target: 300 participants 
1.Km, Mfz, Pza, Eto, Trd 
(6-8 mths) 4 oral drugs will 
continue after 2 consecutive 
negative for 18 mths 
without Km 
2.Lzd, Bdq, Lfx, Pza + Eto 
OR high dose Inh OR Trd 
(6-9 mths) 
MDR only 6 mths 2015 2019 Includes adults ≥18 yrs 
Includes an oral only study arm  
SimpliciTB (NC-008) 
(NCT03338621) 
Sponsor: GATB  
Target: 450 participants 




6 mths 2018 2022 Includes adults ≥18 yrs 












Countries (10) across: 
Africa/Asia/Europe/South America 
Bedaquiline (Bdq), Clofazimine (Cfz), Delamanid (Dlm), Ethambutol (Emb), Ethionamide (Eto), Isoniazid (Inh), Kanamycin (Km), Levofloxicin (Lfx), Linezolid (Lzd), Moxifloxicin (Mfx), 
Pretomanid (Pa), Prothionamide (Pto), Pyrazinamide (Pza), terizidone (Trd) OBR – optimised background regimen Mths – months Wks – weeks, Otsuka – Otsuka Pharmaceutical Development 
& Commercialization, Inc, GATB – Global Alliance for drug development  
IUATLD – International Union Against Tuberculosis and Lung Disease, MSF - Médecins Sans Frontières, UCT – University of Cape Town 
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